Financial Data and Key Metrics Changes - The company reported strong revenue growth of 9% in Q1 2020, with earnings increasing despite the impacts from the COVID-19 pandemic [8][17][38] - Operating income improved by more than EUR 30 million to EUR 648 million, although the operating income margin declined by 60 basis points due to COVID-19 related costs [26][27] - Operating cash flow reached EUR 584 million, representing 13% of revenue, with free cash flow increasing significantly year-over-year to EUR 304 million [34][36] Business Line Data and Key Metrics Changes - Dialysis services and products both experienced growth, with organic growth of 3.8% overall [17][20] - The products business delivered strong reported growth of 10%, with organic growth of 2% despite the pandemic [20][21] - The home business is growing considerably, requiring fewer clinics to be built, contributing to a slower growth rate of clinical infrastructure at 1% [14][15] Market Data and Key Metrics Changes - North America contributed the highest growth in absolute terms with a 10% revenue increase, while EMEA, Asia Pacific, and Latin America followed with 4% growth [18][19] - In North America, same market growth continued with a 3% increase, despite closures as part of a cost optimization program [19] - Asia Pacific's growth of 6% was supported by an increase in the core dialysis business and Care Coordination [19] Company Strategy and Development Direction - The company remains focused on patient care, emphasizing the importance of providing life-saving treatments in a safe environment [10] - The management highlighted the resilience of the business model during the pandemic and confirmed targets for 2020, excluding COVID-19 impacts [9][37] - The company is optimizing its Care Coordination portfolio and has divested some clinics in North America, which positively contributed to margin development [28][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying business fundamentals, despite the challenges posed by the pandemic [28][38] - The company anticipates that most COVID-19 related costs will be covered by government support, particularly from the CARES Act [38] - Future patient volumes and treatment demand remain uncertain, with management monitoring the situation closely [56] Other Important Information - The company has taken extensive measures to ensure the safety of patients and staff during the pandemic, including the use of personal protective equipment [11] - There were no disruptions in manufacturing facilities, and the supply chain remained functional despite global challenges [11] Q&A Session Summary Question: Clarification on guidance and CARES Act funding - Management confirmed that the guidance is inclusive of CARES funding and expects to receive it to cover additional costs incurred due to COVID-19 [44][45] Question: Impact of COVID-19 on patient volumes - Management noted that while there is uncertainty regarding future patient volumes, they are monitoring trends and expect potential increases in acute care demand due to COVID-19 related complications [56] Question: Drivers of Care Coordination growth - The growth in Care Coordination was driven by improved reimbursement rates for vascular care and effective pharmacy operations [60] Question: Status of commercial contracting discussions - Management indicated that discussions are ongoing, with varying perspectives among insurers regarding the management of dialysis patients [89]

Financial Data and Key Metrics Changes - The company achieved a 5% adjusted revenue growth in Q4 2019, confirming guidance for the financial year 2020 [9][14] - Full-year revenue growth reached 5%, aligning with the midpoint of the guidance provided [14] - Adjusted net income remained stable on a constant currency basis [15] Business Line Data and Key Metrics Changes - Health Care Services in the US saw a 3.4% growth in the same market, while EMEA services reported a 5% organic growth [19] - The products business in North America experienced a 16% growth, with core products delivering 4% organic growth [20] - Home dialysis accounted for 13% of all treatments in the US, up 100 basis points from 2018, with a 17% year-on-year growth in home treatments [11][12] Market Data and Key Metrics Changes - North America contributed solidly with a 3% revenue growth at constant currency, while Asia-Pacific showed a strong 7% growth [16] - Latin America experienced a 15% organic growth, driven by high inflation adjustments in the region [20] - The company noted solid growth in Europe, the Middle East, and Africa, alongside a strong increase in Latin America [18] Company Strategy and Development Direction - The company plans to focus on investments in home dialysis and optimizing its clinic network in the US to drive sustainable profitable growth [24] - A new record dividend of EUR1.20 is proposed, marking the 23rd consecutive increase, reflecting a commitment to shareholder value [21] - The company aims to simplify its financial disclosures and guidance to reduce complexity for investors [27][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-to-high single-digit growth in revenue and net income for 2020 [36] - The company is focused on addressing the challenges posed by the coronavirus situation in China while ensuring patient care [16][17] - Management highlighted the importance of staffing and patient education in achieving growth in home dialysis [89] Other Important Information - The company is implementing a global sustainability program to enhance environmental, social, and governance activities [22][23] - The operating cash flow increased in Q4, driven by the implementation of IFRS 16, while free cash flow improved significantly [34][35] Q&A Session Summary Question: Guidance Confidence - Management feels comfortable with the mid-to-high single-digit guidance and does not see the need to narrow it at this time [47] Question: Medicare Advantage Data - Management expects growth in Medicare Advantage but will wait for the fourth quarter enrollment period to provide more insights [48][49] Question: Medicare Advantage Reimbursement Discussions - Discussions with providers about higher reimbursement rates are ongoing, focusing on delivering lower hospital days and better patient outcomes [66] Question: NxStage Acquisition Impact - NxStage will be integrated into the North America business, and its impact will be included in the mid-to-high single-digit guidance moving forward [68] Question: Home Dialysis International Opportunities - Management sees growth potential in international home dialysis, particularly in emerging markets, but acknowledges challenges in infrastructure [56][59] Question: North American EBIT Margin - The strong EBIT performance in North America is attributed to underlying business performance despite some negative adjustments [60][61] Question: Wage Inflation and Staffing - The market for staffing is tight, with a shift towards hiring experienced nurses to manage costs effectively [94] Question: Commercial Insurance Contract Renewals - One large commercial contract is expected to be renewed in 2020, with regional contracts typically renewing in the fourth quarter [95]

Use these links to rapidly review the document Table of contents Index of financial statements Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Commission file number 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Exact name of Registrant as specified in its charter) (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

| --- | --- | --- | |-------------------------------------------|-------|-------| | | | | | Q4 2019 CONFERENCE CALL FEBRUARY 20, 2020 | | | | | | | | Rice Powell - CEO Helen Giza - CFO | | | © Copyright © Copyright | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Use these links to rapidly review the document Table of contents Index of financial statements Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Commission file number 001-32749 FRESENIUS MEDICAL CARE AG & Co. KGaA (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or o ...